Rxsight, INC Form 4 insider transactions

RxSight, Inc. Director Robert Keith Warner was granted 10,752 restricted stock units, increasing his direct beneficial ownership to 41,039 shares, signaling continued alignment with shareholder interests.

RxSight, Inc. Director Shweta Maniar was granted 10,752 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

RxSight, Inc. Director Robert J. Palmisano was granted 10,752 restricted stock units (RSUs) on June 3, 2025, increasing his total beneficial ownership to 41,039 shares of common stock.

RxSight, Inc. Director Julie Andrews has acquired 10,752 Restricted Stock Units (RSUs), increasing her beneficial ownership in the company to 41,039 shares.

RxSight, Inc. Director Juliet Tammenoms Bakker is set to acquire 10,752 restricted stock units on June 3, 2025, as part of her compensation, with vesting contingent on continued service.

RxSight, Inc. Director Jesse Anderson Corley was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of his compensation, aligning his interests with shareholders.

Eric Weinberg, Co-President and Chief Commercial Officer of RxSight, Inc. (RXST), exercised stock options to acquire 188,002 shares of common stock at $3.93 per share, increasing his total beneficial ownership to 496,254 shares.

Shelley Thunen, CFO of RxSight, Inc., reports exercising stock options and acquiring common stock through the company's employee stock purchase plan.

Tamara Fountain, a director at RxSight, Inc., sold 7,000 shares of common stock on March 12, 2025, at a weighted average price of $25.7145, according to a Form 4 filing with the SEC.

Eric Weinberg, Co-President and Chief Commercial Officer of RxSight, Inc., was granted stock options to purchase 125,000 shares of common stock on February 27, 2025.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., was granted 125,000 stock options on February 27, 2025, according to a Form 4 filing with the SEC.

Shelley Thunen, CFO of RxSight, Inc., reports the acquisition of 125,000 stock options on February 27, 2025.

RxSight's President and CEO, Ronald M. Kurtz, acquired 215,000 stock options on February 27, 2025, according to a Form 4 filing with the SEC.

A director of RxSight, Inc. sold 3,519 shares of common stock at an average price of $30.8662 per share under a pre-arranged 10b5-1 trading plan.

Director Jesse Anderson Corley indirectly acquired additional shares of RxSight stock through spousal and trust purchases, while also holding a significant number of shares directly and indirectly through other entities.

RxSight's Co-President and COO, Ilya Goldshleger, exercised stock options and sold shares on November 29, 2024, according to a recent SEC filing.

RxSight director Shweta Maniar sold 3,782 shares of common stock at $45.88 per share on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

An RxSight executive, Ilya Goldshleger, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

An RxSight executive, Ilya Goldshleger, executed stock option exercises and subsequent sales under a pre-arranged 10b5-1 trading plan.

RxSight's Co-President and COO, Ilya Goldshleger, exercised stock options and sold shares under a pre-arranged trading plan.

Director Jesse Anderson Corley of RxSight, Inc. has reported purchasing shares of the company's common stock in multiple transactions.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock on November 4, 2024, according to a Form 4 filing with the SEC.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock between October 16 and October 18, 2024, according to a recent SEC filing.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock on October 4 and October 8, 2024, according to a Form 4 filing with the SEC.

Shelley Thunen, CFO of RxSight, exercised stock options and sold shares of the company's common stock on October 1, 2024, according to a Form 4 filing with the SEC.